Clinical Trials: Neoplasms

Arizona

Tucson ; Research Site:
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

Colorado

Aurora; Research Site:
A Study of R7112 in Patients With Advanced Solid Tumors.

Aurora; Research Site:
A Study of R547 in Patients With Advanced Solid Tumors.

Aurora; Research Site:
A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.

Aurora; Research Site:
A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.

Denver; Research Site:
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

Iowa

Iowa City; University of Iowa Medical Center
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Iowa City; VA of Iowa City
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Maryland

Baltimore; Johns Hopkins University
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Bethesda; Research Site:
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

Bethesda; NIH
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Massachusetts

Boston; Research Site:
A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.

Boston; Research Site:
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.

Michigan

Detroit; Research Site:
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.

Minnesota

Rochester; Mayo Clinic
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Missouri

St. Louis; Mallinckrodt Institute of Radiology
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Nevada

Las Vegas; Research Site:
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.

New Jersey

New Brunswick; Research Site:
A Study of R547 in Patients With Advanced Solid Tumors.

New Brunswick; Research Site:
A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.

New Brunswick; Research Site:
A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.

New York

New York; Research Site:
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

New York; Research Site:
A Study of R7112 in Patients With Advanced Solid Tumors.

New York; New York Presbyterian Hospital-Weill Cornell Medical Center
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

New York; Mount Sinai School of Medicine
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

North Carolina

Charlotte; Research Site:
A Study of R547 in Patients With Advanced Solid Tumors.

Durham; Duke University Medical Center
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Pennsylvania

Philadelphia; Hospital of the University of Pennsylvania
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Rhode Island

Providence; Rhode Island Hospital
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Texas

Houston; Research Site:
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

Houston; Research Site:
A Study of R7112 in Patients With Advanced Solid Tumors.

Houston; Research Site:
A Study of R547 in Patients With Advanced Solid Tumors.

Houston; Research Site:
A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.

Houston; Research Site:
A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.

Houston; Research Site:
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.

Houston; MD Anderson Cancer Center
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

San Antonio; Research Site:
A Study of R7112 in Patients With Advanced Solid Tumors.

San Antonio; Research Site:
A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.

San Antonio; Research Site:
A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.

International

Leuven, Belgium; Research Site:
A Study of 3 Weekly Tubulin Polymerisation Inhibitor (Tub-2) in Patients With Advanced Solid Tumors.

Edmonton, Alberta, Canada; Cross Cancer Institute
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

London, Ontario, Canada; London Health Sciences Centre
Phase 1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Angers, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Bordeaux, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Boulogne-Billancourt, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Caen, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Chambray-Lès-Tours, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Clichy, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Creteil, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Dijon, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Lille, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Lyon, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Marseille, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Montpellier, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Nantes, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Nice, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Paris, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Poitiers, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Reims, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Rouen, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Saint Brieuc, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Strasbourg, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Toulouse, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Villejuif, France; Research Site:
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Barcelona, Spain; Research Site:
A Study of Weekly Tubulin Polymerisation Inhibitor (Tub-2) in Patients With Advanced Solid Tumors.

Aberdeen, United Kingdom; Research Site:
A Study of Weekly Tubulin Polymerisation Inhibitor (Tub-2) in Patients With Advanced Solid Tumors.

Glasgow, United Kingdom; Research Site:
A Study of Weekly Tubulin Polymerisation Inhibitor (Tub-2) in Patients With Advanced Solid Tumors.

Oxford, United Kingdom; Research Site:
A Study of Weekly Tubulin Polymerisation Inhibitor (Tub-2) in Patients With Advanced Solid Tumors.